A clinical-stage biotechnology firm leveraging proprietary mRNA/DNA platforms to develop novel vaccines and immunotherapies for oncology, infectious disease, and autoimmune conditions.
Investors may be attracted to INO's potential for exponential value creation if key clinical trials succeed and regulatory approvals are granted for its high-value oncology and infectious disease candidates. The company's proprietary technology platform offers a cost-effective alternative to traditional vaccine development, positioning it well against emerging competitors in the mRNA space. Strategic partnerships with large pharmaceutical companies provide crucial funding and commercialization expertise, mitigating some of the financial risks associated with clinical-stage development.
The current financial profile shows a severe lack of profitability with over $1 billion in retained earnings deficit and no meaningful revenue generation from its core products. Investors must consider the high probability of further equity dilution to fund ongoing operations given the company's inability to achieve positive cash flow from operations consistently. The biotechnology sector is highly competitive with significant attrition rates, meaning many of INO's pipeline assets could fail before reaching commercialization.
INO develops proprietary mRNA and DNA vaccine platforms to combat infectious diseases, oncology, and autoimmune disorders. The company primarily serves the biotechnology sector with a focus on accelerating drug discovery and manufacturing through its unique synthetic biology technology. Its recent revenue streams are driven by licensing agreements and pre-commercial development activities in high-potential therapeutic areas.
Despite a modest revenue increase from $0.8M in 2023 to $0.2M in 2024 due to restructuring or specific reporting adjustments, the company continues to report significant net losses of over $100M annually. The cash flow from operations turned negative at -$104.1M while financing activities provided $51.5M, indicating heavy reliance on capital markets to sustain R&D efforts. Research and development expenditures reached $75.6M, demonstrating a strong commitment to advancing its clinical pipeline despite the current lack of commercial revenue.
The global mRNA therapeutics market is experiencing rapid growth driven by successful influenza and cancer vaccine candidates, attracting substantial venture capital and strategic investment. Companies in this space are racing to secure first-mover advantages in oncology applications where personalized mRNA vaccines can target specific tumor mutations effectively. Regulatory bodies like the FDA are establishing clearer pathways for accelerated approval of novel biologics, creating both opportunities and challenges for emerging biotech firms.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $10.3M | $832.0K | $217.8K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $10.3M | $832.0K | $217.8K |
| Operating Expenses | $277.8M | $144.8M | $112.6M |
| Operating Income | $-267.6M | $-143.9M | $-112.4M |
| R&D | $187.7M | $86.7M | $75.6M |
| G&A | $90.2M | $47.6M | $37.0M |
| Stock-Based Comp | $22.6M | $11.1M | $6.6M |
| Depreciation | $3.7M | $2.6M | $1.8M |
| Amortization | $496.5K | $145.4K | $0 |
| Other OpEx | $0 | $10.5M | $0 |
| Non-Operating Income | $-10.1M | $8.8M | $5.1M |
| Interest Expense | $1.3M | $1.2M | — |
| Interest Income | — | — | $4.8M |
| Pre-Tax Income | $-277.7M | $-135.1M | $-107.3M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-277.7M | $-135.1M | $-107.3M |
| Discontinued Ops | $-2.2M | $-1 | $0 |
| Net Income | $-279.8M | $-135.1M | $-107.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-279.8M | $-135.1M | $-107.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $315.2M | $153.1M | $97.8M |
| Cash & Equivalents | $46.3M | $14.3M | $65.8M |
| Marketable Securities | $206.7M | $131.0M | $28.3M |
| Accounts Receivable | $1.7M | — | $1.2M |
| Prepaid Expenses | $50.1M | $5.4M | $2.5M |
| Other Current Assets | $10.4M | $2.4M | $0 |
| Long-Term Assets | $33.3M | $17.8M | $15.4M |
| PP&E (Net) | $7.7M | $5.0M | $3.7M |
| Intangibles | $2.1M | $0 | — |
| Goodwill | $10.5M | $0 | — |
| Operating Leases | $10.2M | $9.5M | $8.1M |
| Other LT Assets | $2.7M | $3.4M | $3.6M |
| Total Assets | $348.5M | $171.0M | $113.2M |
| Current Liabilities | $96.9M | $42.6M | $35.3M |
| Current Leases | $2.8M | $2.4M | $2.5M |
| Deferred Revenue | $0 | — | — |
| Other Current Liab | $94.1M | $40.2M | $32.8M |
| Long-Term Liabilities | $29.3M | $11.0M | $9.4M |
| LT Operating Leases | $12.7M | $11.0M | $9.4M |
| Other LT Liab | $16.6M | $0 | $0 |
| Total Liabilities | $126.2M | $53.6M | $44.7M |
| Shareholders' Equity | $222.4M | $117.3M | $68.5M |
| Paid-In Capital | $1.71B | $1.74B | $1.80B |
| Retained Earnings | $-1.49B | $-1.62B | $-1.73B |
| AOCI | $-698.7K | $-662.6K | $-675.7K |
| Total L&E | $348.5M | $171.0M | $113.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-279.8M | $-135.1M | $-107.3M |
| Non-Cash Adjustments | $22.8M | $105.2M | $9.3M |
| Working Capital Changes | $40.8M | $-94.4M | $-6.1M |
| Cash from Operations | $-216.2M | $-124.4M | $-104.1M |
| Capital Expenditures | $969.2K | $320.9K | $487.8K |
| Cash from Investing | $109.6M | $87.4M | $104.1M |
| Cash from Financing | $81.8M | $5.0M | $51.5M |
| FX Effect | $-25.6K | $-3.9K | $32.4K |
| Net Change in Cash | $-24.8M | $-32.0M | $51.5M |
| Beginning Cash | $71.1M | $46.3M | $14.3M |
| Ending Cash | $46.3M | $14.3M | $65.8M |
The company operates through its core technology platform focusing on mRNA vaccine candidates, DNA-based therapeutics, and licensing revenue from strategic partnerships. Key product pipelines include oncology vaccines targeting solid tumors, influenza and respiratory virus vaccines, and therapies for autoimmune diseases like Type 1 diabetes. Revenue is generated via upfront payments, milestone achievements, and royalties from collaborations with major pharmaceutical partners.
The company faces significant financial risk due to its substantial accumulated deficit of $1.73B and recurring net losses, requiring continued equity financing which may dilute existing shareholders. Regulatory approval processes for novel mRNA therapeutics are lengthy and uncertain, posing a threat to the realization of its extensive pipeline assets. Cash burn rates remain high with operating expenses at $112.6M, creating liquidity concerns if external funding markets tighten or partnerships underperform.
INO possesses a proprietary synthetic biology platform that significantly reduces the cost and time required to develop mRNA therapeutics compared to traditional methods. The company holds a robust intellectual property portfolio covering its unique manufacturing processes and formulation technologies, creating a high barrier to entry for competitors. Its diverse pipeline across oncology, infectious disease, and autoimmune segments provides multiple potential revenue streams upon commercialization.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.